Cabozantinib
Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.
| ID | DRUG-CABOZANTINIB |
|---|---|
| Type | Médicament |
| Alias | C.V.CométriqКабозантиніб |
| État | reviewed 2026-04-27 | pending_clinical_signoff |
| Maladies | DIS-HCC DIS-MTC DIS-PHEOCHROMOCYTOMA DIS-RCC |
| Sources | SRC-NCCN-HCC-2025 SRC-NCCN-KIDNEY-2025 SRC-NCCN-THYROID-2025 |
Faits sur les drogues
| Catégorie | Inhibiteur multikinase (MET, VEGFR1-3, RET, AXL, KIT, FLT3, ROS1) |
|---|---|
| Mécanisme | Oral multi-targeted TKI inhibiting MET, VEGFR1-3, RET, AXL, KIT, FLT3, and ROS1. Approved for medullary thyroid carcinoma (EXAM trial — capsule formulation Cometriq 140 mg), renal cell carcinoma (METEOR / CABOSUN — tablet formulation Cabometyx 60 mg), HCC (CELESTIAL 2L), and DTC (COSMIC-311). Activity in MTC independent of RET mutation status — option for RET-WT MTC where selective RET inhibitors are not appropriate. |
| Dose typique | Medullary thyroid carcinoma (Cometriq capsules): 140 mg PO once daily on empty stomach (≥1 h before / ≥2 h after food). RCC / HCC / DTC (Cabometyx tablets): 60 mg PO once daily on empty stomach. Capsule and tablet formulations are NOT bioequivalent. |
| Ukraine enregistrée | Faux |
| NSZU remboursé | Faux |
| Ukraine vérifiée pour la dernière fois | 2026-04-27 |
Avertissements
- Perforation GI / fistule
- Hémorragie grave / fatale
Notes
EXAM (Schoffski 2012, MTC): cabozantinib 140 mg vs placebo improved PFS 11.2 vs 4.0 mo; OS benefit in M918T-mutant subgroup. ZETA (vandetanib) is the alternative MTC multikinase TKI; both predate RET-selective era. Modern preferred sequence in advanced RET-mutant MTC: selpercatinib > pralsetinib > cabozantinib / vandetanib (toxicity pushes selectives first). For RET-WT MTC (RAS-mutant or unknown), cabozantinib retains primary role. Capsule (Cometriq) and tablet (Cabometyx) are NOT interchangeable — different bioavailability per FDA prescribing information.
Utilisé par
Indication
IND-PHEO-METASTATIC-1L-CABOZANTINIB- IND-PHEO-METASTATIC-1L-CABOZANTINIB
Protocole thérapeutique
REG-CABOZANTINIB-HCC- Cabozantinib (HCC, 2L)REG-CABOZANTINIB-MTC-1L- Cabozantinib en monothérapie (MTC RET-WT avancé/progressif, 1L; ou RET-mutant où RET-se...REG-CABOZANTINIB-PHEO- Cabozantinib en monothérapie (phéochromocytome non métastatique non-avide MIBG/paragangliome,...REG-CABOZANTINIB-RCC- Cabozantinib en monothérapie (RCC, 2L)REG-NIVO-CABO-RCC- Nivolumab + cabozantinib (RCC, 1L)